CellSeed Inc. (7776) AI Stock Analysis

• Market Cap: ¥12.14B
• Dividend Yield: N/A
• Average Volume (3M): 621.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -42.49%
• EPS Growth: -2.37%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.31
• Shares Outstanding: 38,293,820
• 10 Day Avg. Volume: 981,780
• 30 Day Avg. Volume: 621,903
• PEG Ratio: -0.34
• Price to Book (P/B): 7.08
• Price to Sales (P/S): 107.39
• P/FCF Ratio: -8.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ¥358.00 ▲(38.22% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily constrained by weak financial performance—sharp revenue deterioration, very large losses, and persistent cash burn—despite relatively low leverage. Technicals are supportive in the near term (price above key shorter moving averages with positive MACD), but valuation is hindered by negative earnings and no dividend data.

Positive Factors

Conservative leverage

Low reported debt-to-equity provides durable financial flexibility for a cash-burning biotech. Conservative leverage reduces near-term interest burden and preserves borrowing capacity to fund R&D or bridge financing needs, supporting survival through development cycles.

Healthy gross margins

Sustained gross margins near 48–69% indicate strong underlying unit economics in cell-based products. This margin profile can support future operating leverage as revenues recover, enabling more efficient conversion of incremental sales into operating profit over time.

Specialized tech & focused model

Niche focus on cell sheet engineering creates barriers to entry through specialized know‑how and manufacturing capabilities. A concentrated product and service set supports deep expertise, potential IP advantages, and durable positioning in regenerative-medicine segments.

Negative Factors

Persistent cash burn

Repeated annual negative operating and free cash flow indicates the business cannot self-fund development or commercialization. Persistent cash burn raises long-term funding and dilution risk, forcing reliance on external financing which can pressure strategy and execution.

Sharp revenue decline

A large, recent revenue drop undermines scale needed to absorb fixed costs in manufacturing and R&D. Continued top-line volatility impedes predictable margin expansion, delays path to profitability, and increases the challenge of demonstrating commercial traction to partners or funders.

Large operating losses & equity erosion

Very large negative margins and a material decline in shareholder equity signal deep profitability issues and capital erosion. This weakens resilience to setbacks, increases dilution risk from future financings, and burdens management with rebuilding capital while pursuing development milestones.

CellSeed Inc. Business Overview & Revenue Model

Company Description

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

How the Company Makes Money

CellSeed Inc. generates revenue through multiple avenues including the commercialization of its cell sheet technology and related products, partnerships with healthcare institutions for research and development, and licensing agreements for its patented technologies. The company collaborates with pharmaceutical firms and research organizations, leveraging its innovative approaches to attract investments and drive product development. Additionally, CellSeed may earn income through regulatory approvals and grants aimed at advancing its therapeutic innovations, further strengthening its financial position.

CellSeed Inc. Financial Statement Overview

Summary

Income statement and cash flow are very weak: 2025 revenue fell sharply (−56.7% YoY) while operating losses remain extremely large (net margin about −1,319%) and cash burn is persistent (negative operating cash flow and free cash flow every year, worsening again in 2025). Balance sheet leverage is relatively conservative (low debt-to-equity), but equity declined materially in 2025 and returns on equity are deeply negative, reinforcing funding/dilution risk.

Income Statement

Revenue has been volatile and recently deteriorated, with 2025 revenue down sharply (−56.7% YoY) after modest growth in 2024. Gross margin is consistently healthy for the sector (~48%–69%), indicating solid underlying unit economics, but operating losses remain very large and widened in 2025 (net margin about −1,319%), reflecting a cost base that is far above the current revenue scale. Overall, profitability trajectory is negative despite decent gross profitability.

Balance Sheet

Leverage appears conservative, with debt-to-equity generally low (~0.07–0.15) and total debt relatively modest. However, shareholder equity declined materially in 2025 versus 2024, and returns on equity are deeply negative across all years, consistent with ongoing losses and potential dilution/erosion risk if losses persist. The balance sheet provides some financial flexibility, but the trend in equity is a key watch item.

Cash Flow

Cash burn is significant and persistent: operating cash flow is negative every year (roughly −¥0.70B to −¥0.99B), and free cash flow is also consistently negative (roughly −¥0.71B to −¥1.02B), worsening again in 2025. While free cash flow tracks net losses (free cash flow roughly in line with net income in magnitude), the business has not demonstrated a path to self-funding operations, increasing reliance on external financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	83.68M	193.28M	190.13M	126.43M	161.67M
Gross Profit	42.75M	110.11M	107.16M	61.02M	84.04M
EBITDA	-1.05B	-855.49M	-836.52M	-750.00M	-905.67M
Net Income	-1.10B	-859.84M	-846.53M	-759.68M	-912.87M
Balance Sheet
Total Assets	1.66B	2.43B	2.47B	1.54B	1.41B
Cash, Cash Equivalents and Short-Term Investments	1.32B	2.13B	2.16B	1.07B	846.67M
Total Debt	132.92M	143.75M	151.25M	158.75M	160.00M
Total Liabilities	387.46M	269.88M	301.05M	365.58M	363.58M
Stockholders Equity	1.27B	2.16B	2.16B	1.18B	1.04B
Cash Flow
Free Cash Flow	-1.02B	-884.47M	-801.07M	-733.60M	-908.15M
Operating Cash Flow	-988.98M	-866.10M	-779.43M	-718.01M	-817.15M
Investing Cash Flow	-26.72M	-18.37M	56.31M	61.73M	-110.44M
Financing Cash Flow	200.30M	855.48M	1.81B	881.81M	396.88M

CellSeed Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 259.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Positive. The current price of 259 is below the 20-day moving average (MA) of 319.30, below the 50-day MA of 297.34, and below the 200-day MA of 412.00, indicating a neutral trend. The MACD of 11.44 indicates Negative momentum. The RSI at 57.22 is Neutral, neither overbought nor oversold. The STOCH value of 32.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7776.

CellSeed Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥16.11B	-53.38	―	―	1.24%	-33.41%
4889	58 Neutral	¥23.43B	-89.33	―	―	-32.68%	―
7096	56 Neutral	¥8.96B	46.28	―	―	2.99%	-52.75%
7774	55 Neutral	¥27.57B	-61.60	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥12.14B	-10.84	―	―	-42.49%	-2.37%
4599	43 Neutral	¥18.24B	-9.63	―	―	―	11.34%